



Inland Empire Health Plan

PHARMACY TIMES

BY IEHP PHARMACEUTICAL SERVICES DEPARTMENT

June 06, 2022

URGENT: Recalls, Market Withdrawals, & Safety Alerts

Dear IEHP Providers,

According to the FDA recall guidance, Title 21 Code of Federal Regulations Part 7 (21 CFR part 7), recalled products must be promptly removed or corrected. In an effort to promote health and wellness of our members, please review your records and notify members who may have been impacted by these recalls and market withdrawals.

Product Name	Product Code	Lot # and Exp. Date	Classification	Recalling Firm
SyrSpend SF 500mL and 4L	NDC: 51552-1123-05; 51552-1123-09	A67185, A67186 Exp. 08/31/2024	MW	Fagron Inc.
NAD+ Nicotinamide Adenine Dinucleotide Lyophilized powder for reconstitution, Multi-Dose 500 mg Per Vial	NDC: 73198-0083-00	E24026 BUD: 5/26/2022, E42112 BUD: 5/12/2022, E48024 BUD: 2/2/2022, F24014 BUD: 6/14/2022, G48028 BUD: 7/28/2022, H24016 BUD: 8/16/2022, H42010 BUD 8/10/2022, H48030 BUD: 8/11/2022, I47003 BUD: 8/11/2022	Class II	Olympia Compounding Pharmacy dba Olympia Pharmacy
Diluent for Reconstitution Each ML contains: 1.5% Benzyl Alcohol NF, Sterile Water for Injection USP, 10 mL Multi-Dose vial	NDC: 73198-0113-10	D41012 BUD 4/12/2022, D41212 BUD: 4/12/2022, D47026 BUD: 4/26/2022, E41017 BUD: 5/17/2022, E41018 BUD: 5/18/2022, E47004 BUD: 5/4/2022, E47024 BUD: 5/24/2022, E47026 BUD: 5/26/2022, E48005 BUD: 5/5/2022, G47014 BUD: 7/14/2022, H48816 BUD: 8/16/2022	Class II	Olympia Compounding Pharmacy dba Olympia Pharmacy
Sermorelin Acetate, Lyophilized powder for reconstitution, Multi-Dose vials, Packaged as 3 mg or 9 mg per vial	NDC: 73198-0059-00; 73198-0060-00	D41019 BUD: 4/19/2022; D41112 BUD: 4/12/2022, D47028 BUD: 4/28/2022, F24009 BUD 3/4/2022, F41001 BUD: 6/1/2022, G48006 BUD: 7/14/2022, G48008 BUD: 7/8/2022, G48012 BUD: 7/12/2022, G48014 BUD: 7/14/2022, G48019 BUD: 7/9/2022, I24009 BUD: 9/9/2022, I41107 BUD: 9/7/2022	Class II	Olympia Compounding Pharmacy dba Olympia Pharmacy



A Public Entity

Inland Empire Health Plan

QM-2 Papaverine 30 mg/mL . Phentolamine 3 mg/mL . Alprostadil 60 mcg/mL . Atropine 0.2 mg/mL, Multi-Dose 10 mL vial	NDC: 73198-0018-10	D41219 BUD: 4/19/2022, I24C13 BUD: 9/13/2022	Class II	Olympia Compounding Pharmacy dba Olympia Pharmacy
T-105, Papaverine 30mg/mL . Phentolamine 1mg/ml . PGE 10mcg/ml, Packaged as 10 ml Multi-Dose vial; 5 ml Multi-Dose vial; 2.5 ml Multi-Dose vial	NDC: 73198-0005-10; 73198-0005-05; 73198-0005-03	D41412 BUD: 4/22/2022, E41F10 BUD: 5/10/2022, E41G10 BUD: 5/10/2022, F24D21 BUD: 6/21/2022 ; D41512 BUD: 4/12/2022; F42B21 BUD: 6/21/2022, H42B03 BUD: 8/3/2022, H42C03 BUD: 8/3/2022	Class II	Olympia Compounding Pharmacy dba Olympia Pharmacy
Formula F9, Papaverine 0.9mg/ml . Phentolamine 0.1mg/ml . PGE 20mcg/mL Atropine 0.01mg/ml, Multi-Dose 10 ml vial	NDC: 73198-0004-10	D41C19 BUD: 4/19/2022, I42C13 BUD: 9/13/2022, I42B13 BUD: 9/13/2022	Class II	Olympia Compounding Pharmacy dba Olympia Pharmacy
AT-6, Papaverine 40mg/ml . Phentolamine 4mg/ml . Atropine 0.3mg/ml, Multi-Dose 10 ml vial	NDC: 73198-0040-10	D41E20 BUD: 4/20/2022, D41F20 BUD: 4/20/2022, G41C13 BUD: 7/13/2022, G41B13 BUD: 7/13/2022	Class II	Olympia Compounding Pharmacy dba Olympia Pharmacy
AT-1, Papaverine 8mg/ml . Phentolamine 2mg/ml . Atropine 0.2mg/ml, Multi-Dose 10 ml vial	NDC: 73198-0039-10	F41C28 BUD: 6/28/2022, F41B28 BUD: 6/28/2022	Class II	Olympia Compounding Pharmacy dba Olympia Pharmacy
NB-243, Papaverine 30mg/ml . Phentolamine 3mg/ml . Alprostadil 20mcg/ml, 10ml Multi-Dose vials	NDC: 73198-0009-10	I24C28 BUD: 9/28/2022, D41119 BUD: 4/19/2022, F41321 BUD: 6/21/2022, I24128 BUD: 9/28/2022	Class II	Olympia Compounding Pharmacy dba Olympia Pharmacy
T-106, Papaverine 30 mg/mL . Phentolamine 1 mg/mL . Alprostadil 25 mcg/mL, Packaged as 10 mL Multi-Dose vial; 5 mL Multi-Dose vial	NDC: 73198-0013-10; 73198-0013-05	E24510 BUD: 5/10/2022, E24610 BUD: 5/10/2022; H42H03 BUD: 8/3/2022, E24810 BUD: 5/10/2022, H42203 BUD: 8/3/2022	Class II	Olympia Compounding Pharmacy dba Olympia Pharmacy
T-101, Papaverine 17.65 mg/mL . Phentolamine 0.59 mg/mL . Alprostadil 5.9 mcg/mL. Packaged as 10 mL Multi-Dose vial; 5 mL Multi-Dose vial	NDC: 73198-0014-10; 73198-0014-05	E41B10 BUD: 5/10/2022; E41B08 BUD: 5/10/2022, I41C08 BUD: 9/8/2022, I41D08 BUD: 9/8/2022, E41C10 BUD: 5/10/2022	Class II	Olympia Compounding Pharmacy dba Olympia Pharmacy



A Public Entity

Inland Empire Health Plan

SB-4, Papaverine 30 mg/mL . Phentolamine 3 mg/mL . Alprostadil 40 mcg/mL, 10 mL Multi-Dose vial	NDC: 73198-0023-10	E41C18 BUD: 5/18/2022, E41D18 BUD: 5/18/2022, G42D20 BUD: 7/20/2022, G42B20 BUD: 7/20/2022	Class II	Olympia Compounding Pharmacy dba Olympia Pharmacy
SB-5, Papaverine 30 mg/mL . Phentolamine 3 mg/mL . PGE 50 mcg/mL, 10 mL, Multi-Dose vial	NDC: 73198-0024-10	E48B18 BUD: 5/18/2022, E48D18 BUD: 5/18/2022, H24D31 BUD: 8/31/2022; E48C18 BUD: 5/18/2022	Class II	Olympia Compounding Pharmacy dba Olympia Pharmacy
SB-6, Papaverine 30 mg/mL . Phentolamine 3 mg/mL . PGE 60 mcg/mL, Multi-Dose 10 mL vial	NDC: 73198-0025-10	E41H18 BUD: 5/18/2022, G41319 BUD: 7/19/2022	Class II	Olympia Compounding Pharmacy dba Olympia Pharmacy
ST-1, Papaverine 30 mg/mL . Phentolamine 1.5 mg/mL . Alprostadil 50 mcg/ml, 10 mL Multi-Dose vial	NDC: 73198-0011-10	H24F03 BUD: 8/3/2022, H24E03 BUD: 8/3/2022	Class II	Olympia Compounding Pharmacy dba Olympia Pharmacy
ST-2, Papaverine 30 mg/mL . Phentolamine 3 mg/mL . Alprostadil 100 mcg/mL, 10 mL Multi-Dose vial	NDC: 73198-0012-10	F41C21 BUD: 6/21/2022, G42013 BUD: 7/13/2022, H41C31 BUD: 8/31/2022, F41D21 BUD: 6/21/2022	Class II	Olympia Compounding Pharmacy dba Olympia Pharmacy
QM-3, Papaverine 30 mg/mL . Phentolamine 3 mg/mL . Alprostadil 150 mcg/mL . Atropine 0.2 mg/mL, 10 mL Multi-Dose vial	NDC: 73198-0019-10	E42B12 BUD: 5/12/2022, E42C12 BUD: 5/12/2022, E42D12 BUD: 5/12/2022, H24B23 BUD: 8/23/2022, H24C23 BUD: 8/23/2022, H24D23 BUD: 8/23/2022	Class II	Olympia Compounding Pharmacy dba Olympia Pharmacy
QM-4, Papaverine 30 mg/mL . Phentolamine 3 mg/mL . Alprostadil 300 mcg/mL . Atropine 0.2 mg/mL, 10 mL Multi-Dose vial	NDC: 73198-0020-10	E41027 BUD: 5/27/2022, I24E13 BUD: 9/13/2022	Class II	Olympia Compounding Pharmacy dba Olympia Pharmacy
RE-1, Papaverine 30 mg/mL . Phentolamine 3 mg/mL . Alprostadil 200 mcg/mL, Packaged in 10 mL Multi-Dose vial; 2.5 mL Multi-Dose vial	NDC: 73198-0015-10; 73198-0015-03	E47B18 BUD: 5/18/2022; b) E47C18 BUD: 5/18/2022, H24G31 BUD: 8/31/2022	Class II	Olympia Compounding Pharmacy dba Olympia Pharmacy
RE-2, Papaverine 30 mg/mL . Phentolamine 3 mg/mL . Alprostadil 300 mcg/mL, Multi-Dose 10 mL vial	NDC: 73198-0016-10	E42G11 BUD: 5/11/2022, H41003 BUD: 8/3/2022; H41B03 BUD: 8/3/2022	Class II	Olympia Compounding Pharmacy dba Olympia Pharmacy
BIMIX-3, Papaverine 30 mg/mL . Phentolamine 3 mg/mL, 10 mL Multi-Dose vial	NDC: 73198-0027-10	F24C10 BUD: 6/10/2022	Class II	Olympia Compounding Pharmacy dba Olympia Pharmacy



A Public Entity

Inland Empire Health Plan

FA, Papaverine 20 mg/mL . Phentolamine 2 mg/mL . Alprostadil 20 mcg/mL . Atropine 0.2 mg/mL, 10 mL Multi-Dose vial	NDC: 73198-0006-10	F41414 BUD: 6/14/2022, F41C14 BUD: 6/14/2022, I24E28 BUD: 9/28/2022, I24F28 BUD: 9/28/2022	Class II	Olympia Compounding Pharmacy dba Olympia Pharmacy
PGE-1, Alprostadil 40 mcg/mL, 10ml Multi-Dose vial	NDC: 73198-0028-10	I24028 BUD: 9/28/2022,F47C30 BUD: 6/30/2022, F47B30 BUD: 6/30/2022	Class II	Olympia Compounding Pharmacy dba Olympia Pharmacy
PGE-2, Alprostadil 80 mcg/mL, 10ml Multi-Dose vial	NDC: 73198-0029-10	F48102 BUD: 6/2/2022	Class II	Olympia Compounding Pharmacy dba Olympia Pharmacy
PGE-3, Alprostadil 150 mcg/mL, 10ml Multi-Dose vial	NDC: 73198-0030-10	G24C19 BUD: 7/19/2022	Class II	Olympia Compounding Pharmacy dba Olympia Pharmacy
T-50, Papaverine 8 mg/mL . Phentolamine 0.29 mg/mL . Alprostadil 2.9 mcg/mL, 10ml Multi-Dose vial	NDC: 73198-0022-10	G24F01 BUD: 7/1/2022, G41316 BUD: 7/16/2022, H24B03 BUD: 8/3/2022, H24C03 BUD: 8/3/2022	Class II	Olympia Compounding Pharmacy dba Olympia Pharmacy
Formula F2, Papaverine 9 mg/mL . Phentolamine 1 mg/mL . Alprostadil 10 mcg/mL . Atropine 0.1 mg/mL, 10 mL Multi-Dose vial	NDC: 73198-0002-10	G48C20 BUD: 7/20/2022, G48B20 BUD: 7/22/2022	Class II	Olympia Compounding Pharmacy dba Olympia Pharmacy
Phenylephrine 1 mg/mL, 5 mL Multi-Dose vial	NDC: 73198-0021-05	H47030 BUD: 8/30/2022	Class II	Olympia Compounding Pharmacy dba Olympia Pharmacy
Testosterone Cypionate 200 mg/mL (in Grapeseed Oil), Packaged in 10 mL Multi-Dose vial; 5 mL Multi- Dose vial	NDC: 73198-0054-10; 73198-0054-05	D48027 BUD: 4/27/2022,E47017 BUD: 5/17/2022, F42007 BUD: 6/7/2022, F42107 BUD: 6/7/2022, F42207 BUD: 6/7/2022, F48009 BUD: 6/9/2022, F48109 BUD: 6/9/2022, H47003 BUD: 8/3/2022; F24024 BUD: 6/24/2022	Class II	Olympia Compounding Pharmacy dba Olympia Pharmacy
Testosterone Cypionate 200 mg/mL, (in Sesame	NDC: 73198-0055-10; 73198-0055-05	E48019 BUD: 5/19/2022, F42109 BUD: 6/9/2022,	Class II	Olympia Compounding

10801 6th St., Suite 120, Rancho Cucamonga, CA 91730

Tel (909) 890-2049 Fax (909) 890-2058

Visit our web site at: www.iehp.org

A Public Entity



A Public Entity

Inland Empire Health Plan

Oil), Packaged in 10 mL Multi-Dose vial; 5 mL Multi-Dose vial		F42C09 BUD: 6/9/2022, G47012 BUD: 7/12/2022, G47112 BUD: 7/12/2022; F42B09 BUD: 6/9/2022		Pharmacy dba Olympia Pharmacy
Ultratest, Testosterone Cypionate 160 mg/mL, Testosterone Propionate 40 mg/mL, 10 mL Multi-Dose vial	NDC: 73198-0058-10	E48020 BUD: 5/20/2022; G47006 BUD: 7/6/2022	Class II	Olympia Compounding Pharmacy dba Olympia Pharmacy
Hydroxocobalamin B12, 1 mg/mL, 30 mL Multi-Dose vial	NDC: 73198-0080-30	D48026 BUD: 4/26/2022, E48025 BUD: 5/25/2022, G48B21 BUD: 7/21/2022, G48C21 BUD: 7/21/2022	Class II	Olympia Compounding Pharmacy dba Olympia Pharmacy
Sinacalide. Lyophilized powder for reconstitution. 5 mcg per Multi-Dose vial	NDC: 73198-0082-00	F24018 BUD: 6/18/2022; G47021 BUD: 7/21/2022	Class II	Olympia Compounding Pharmacy dba Olympia Pharmacy
NAD+ Nicotinamide Adenine Dinucleotide Lyophilized powder for reconstitution, Multi-Dose 500 mg Per Vial	NDC: 73198-0083-00	F41116 BUD: 6/16/2022	Class II	Olympia Compounding Pharmacy dba Olympia Pharmacy
Lidocaine 2.5% and Prilocaine 2.5% Cream, USP, packaged in 5 g tubes; 30 g tubes	NDC: 00591-2070-72; 00591-2070-30	16291 Exp. 01/2024; 16469 Exp. 02/2024; 16255 Exp. 11/2022; 16256, 16412 Exp. 02/2024; 16257, 16258 Exp. 12/2022; 16505, 6506 Exp. 03/2024; 16627, 16786, 16787, 16820 Exp. 04/2024.	Class II	Teva Pharmaceuticals USA Inc
Losartan Potassium 50 mg Tablet, 30-count blister card; 60-count blister card	NDC: 70518-3282-01; 70518-3282-00	B1467803-120621 Exp. 06/30/2022 ; J0585793-121721 Exp. 12/31/2022	Class II	RemedyRepack Inc.
Losartan Potassium 50 mg Tablets	NDC Not Provided	E13210, E2521H, E2621F Exp. 05/31/2023	Class II	Preferred Pharmaceuticals, Inc.
Zonisamide 25 mg Capsules	NDC: 68462-128-01	29200052 Exp. 04/30/2023	Class II	Glenmark Pharmaceuticals Inc., USA



A Public Entity

Inland Empire Health Plan

Zonisamide 50 mg Capsules	NDC: 68462-0129-01	29200064 Exp. 05/31/2023	Class II	Glenmark Pharmaceuticals Inc., USA
Zonisamide 100 mg Capsules	NDC: 68462-0130-01; 68462-0130-05	29200053, 29200054 Exp. 04/30/2023	Class II	Glenmark Pharmaceuticals Inc., USA
Losartan Potassium 25 mg Tablets	NDC: 68180-0376-03; 68180-0376-09	H001333, exp. date Nov-22 H002786, exp. date Jan-23 H101282, exp. date Feb-23 H001189, exp. date Nov-22 H002955, exp. date Jan-23 H101285, exp. date Feb-23 H001714, exp. date Dec-22 H000523, exp. date Jan-23 H101989, exp. date Mar-23 H001940, exp. date Dec-22 H003080, exp. date Jan-23 H101789, exp. date Mar-23 H002388, exp. date Jan-23 H100109, exp. date Feb-23 H002389, exp. date Jan-23 H100642, exp. date Feb-23 H000848, exp. date Nov-22, H002002, exp. date Dec-22 H100110, exp. date Feb-23 H001190, exp. date Nov-22 H002003, exp. date Dec-22 H100111, exp. date Feb-23 H001191, exp. date Nov-22 H002489, exp. date Jan-23 H100146, exp. date Feb-23 H001192, exp. date Nov-22 H002390, exp. date Jan-23 H100147, exp. date Feb-23 H001058, exp. date Nov-22 H002486, exp. date Jan-23 H101283, exp. date Feb-23 H000985, exp. date Nov-22 H002487, exp. date Jan-23 H101284, exp. date Feb-23 H001059, exp. date Nov-22 H002488, exp. date Jan-23 H100643, exp. date Feb-23 H001275, exp. date Nov-22 H002787, exp. date Jan-23 H100644, exp. date Mar-23 H001715, exp. date Dec-22 H002957, exp. date Jan-23 H100869, exp. date Mar-23 H001716, exp. date Dec-22 H002958, exp. date Jan-23 H101990, exp. date Mar-23 H001717, exp. date Dec-22 H003079, exp. date Jan-23 H101991, exp. date Mar-23 H001718, exp. date Dec-22 H003121, exp. date Feb-23 H101992, exp. date Mar-23 H001941, exp. date Dec-22 H003122, exp. date Feb-23 H000847, exp. date Nov 2022	Class II	Lupin Pharmaceuticals Inc.
Losartan Potassium 50 mg Tablets	NDC: 68180-0377-03; 68180-0377-09	H903720, exp. date Oct-22 H001876, exp. date Dec-22 H003002, exp. date Jan-23 H903774, exp. date Oct-22 H001877, exp. date Dec-22 H003003, exp. date Feb-23 H000849, exp. date Nov-22	Class II	Lupin Pharmaceuticals Inc.



A Public Entity

Inland Empire Health Plan

		<p>H002127, exp. date Dec-22 H003004, exp. date Feb-23 H001412, exp. date Nov-22 H002128, exp. date Dec-22 H003123, exp. date Feb-23 H001413, exp. date Nov-22 H002643, exp. date Jan-23 H003124, exp. date Feb-23 H001414, exp. date Nov-22 H002644, exp. date Jan-23 H101129, exp. date Feb-23 H001430, exp. date Nov-22 H002645, exp. date Jan-23 H101147, exp. date Mar-23 H001526, exp. date Dec-22 H002839, exp. date Jan-23 H102139, exp. date Mar-23 H001652, exp. date Dec-22 H002840, exp. date Jan-23 H102158, exp. date Mar-23 H000605, exp. date Jan-23 H001599, exp. date Dec-22 H100148, exp. date Feb-23 H001401, exp. date Nov-22 H001875, exp. date Dec-22 H102043, exp. date Mar-23 H001063, exp. date Nov-22 H002126, exp. date Dec-22 H101495, exp. date Mar-23 H001188, exp. date Nov-22 H002838, exp. date Jan-23 H001455, exp. date Nov-22 H002642, exp. date Jan-23</p>		
<p>Losartan Potassium 100 mg Tablets</p>	<p>NDC: 68180-0378-03; 68180-0378-09</p>	<p>H903573, exp. date Oct-22 H002311, exp. date Dec-22 H100713, exp. date Mar-23 H001060, exp. date Nov-22 H002620, exp. date Jan-23 H100714, exp. date Mar-23 H001456, exp. date Nov-22 H002313, exp. date Jan-23 H100934, exp. date Mar-23 H001457, exp. date Nov-22 H002490, exp. date Jan-23 H100935, exp. date Mar-23</p>	<p>Class II</p>	<p>Lupin Pharmaceuticals Inc.</p>



A Public Entity

Inland Empire Health Plan

		<p>H001470,, exp. date Nov-22 H002842, exp. date Jan-23 H101081, exp. date Mar-23 H001484, exp. date Dec-22 H002843, exp. date Jan-23 H101148, exp. date Mar-23 H001485, exp. date Dec-22 H002995, exp. date Jan-23 H101639, exp. date Mar-23 H001708, exp. date Dec-22 H003199, exp. date Feb-23 H101480, exp. date Mar-23 H002314, exp. date Dec-22 H003200, exp. date Feb-23 H101822, exp. date Mar-23 H001709, exp. date Dec-22 H100028, exp. date Feb-23 H101481, exp. date Mar-23 H002001, exp. date Dec-22 H100712, exp. date Feb-23 H102288, exp. date Mar-23 H001991, exp. date Dec-22 H100221, exp. date Feb-23 H002000, exp. date Dec-22 H100222, exp. dateFeb-23 H903582, exp. date Oct-22 H001707, exp. dateDec-22 H100220, exp. date Feb-23 H000556,, exp. date Nov-22 H003045, exp. date Dec-22 H100901, exp. date Mar-23 H000557, exp. date Nov-22 H002391, exp. date Dec-22 H101078, exp. date Mar-23 H001061, exp. date Nov-22 H002312, exp. date Jan-23 H101479, exp. date Mar-23 H001062, exp. date Nov-22 H002517, exp. date Jan-23 H101496, exp. date Mar-23 H001431, exp. date Nov-22 H002841, exp. date Jan-23 H101821, exp. date Mar-23 H002341, exp. date Nov-22 H003044, exp. date Feb-23 H102286, exp. date Mar-23 H001706, exp. date Dec-22 H003198, exp. date Feb-23 H102287, exp. date Mar-23</p>		
<p>Losartan Potassium and Hydrochlorothiazide 50 mg/12.5 mg Tablets</p>	<p>NDC: 68180-0215-06; 68180-0215-09</p>	<p>H001149 4/30/2022 68180-215-06 H001602 5/31/2022 68180-215-06 H001884 6/30/2022 68180-215-06 H002539 8/31/2022 68180-215-06 H100944 4/30/2023 68180-215-06 H101054 4/30/2023 68180-215-06 H001150 4/30/2022 68180-215-09 H001151 4/30/2022 68180-215-09 H001152 4/30/2022 68180-215-09 H001532 5/31/2022 68180-215-09 H001533 5/31/2022 68180-215-09 H001534 5/31/2022 68180-215-09 H001535 5/31/2022 68180-215-09 H001536 5/31/2022 68180-215-09 H001603 5/31/2022 68180-215-09 H001604 5/31/2022 68180-215-09 H001605 5/31/2022 68180-215-09 H001606 5/31/2022 68180-215-09 H001607 5/31/2022 68180-215-09 H001608 5/31/2022 68180-215-09 H001885 6/30/2022 68180-215-09 H001886 6/30/2022 68180-215-09 H001887 6/30/2022</p>	<p>Class II</p>	<p>Lupin Pharmaceuticals Inc.</p>



A Public Entity

Inland Empire Health Plan

		<p>68180-215-09 H001888 6/30/2022 68180-215-09 H002171 7/31/2022 68180-215-09 H002172 7/31/2022 68180-215-09 H002173 7/31/2022 68180-215-09 H002174 7/31/2022 68180-215-09 H002175 7/31/2022 68180-215-09 H002540 8/31/2022 68180-215-09 H002541 8/31/2022 68180-215-09 H002542 8/31/2022 68180-215-09 H002543 8/31/2022 68180-215-09 H002544 8/31/2022 68180-215-09 H002545 8/31/2022 68180-215-09 H002976 10/31/2022 68180-215-09 H002977 10/31/2022 68180-215-09 H002978 10/31/2022 68180-215-09 H003131 11/30/2022 68180-215-09 H003132 11/30/2022 68180-215-09 H003133 11/30/2022 68180-215-09 H003134 11/30/2022 68180-215-09 H003135 11/30/2022 68180-215-09 H003136 11/30/2022 68180-215-09 H100302 1/31/2023 68180-215-09 H100303 1/31/2023 68180-215-09 H100304 1/31/2023 68180-215-09 H100340 1/31/2023 68180-215-09 H100341 1/31/2023 68180-215-09 H100657 2/28/2023 68180-215-09 H100658 2/28/2023 68180-215-09 H100659 2/28/2023 68180-215-09 H100660 2/28/2023 68180-215-09 H100661 2/28/2023 68180-215-09 H100662 2/28/2023 68180-215-09 H100945 4/30/2023 68180-215-09 H100946 4/30/2023 68180-215-09 H101051 4/30/2023 68180-215-09 H101052 4/30/2023 68180-215-09 H101053 4/30/2023 68180-215-09 H101055 4/30/2023 68180-215-09 H101056 4/30/2023 68180-215-09 H101057 4/30/2023 68180-215-09 H101058 4/30/2023 68180-215-09 H101286 5/31/2023 68180-215-09 H101287 5/31/2023 68180-215-09 H101288 5/31/2023 68180-215-09 H101289 5/31/2023 68180-215-09 H101581 6/30/2023 68180-215-09 H101582 6/30/2023 68180-215-09 H101583 6/30/2023 68180-215-09 H101584 7/31/2023 68180-215-09 H101585 7/31/2023 68180-215-09 H101790 7/31/2023 68180-215-09 H101791 7/31/2023 68180-215-09 H102078 8/31/2023 68180-215-09 H102079 8/31/2023 68180-215-09 H102080 9/30/2023 68180-215-09 H102118 9/30/2023 68180-215-09 H102119 9/30/2023 68180-215-09 H102120 9/30/2023 68180-215-09 H102125 9/30/2023 68180-215-09 H102126 9/30/2023 68180-215-09</p>		
<p>Losartan Potassium and Hydrochlorothiazide 100 mg/25 mg Tablets</p>	<p>NDC: 68180-0217-06; 68180-0217-09</p>	<p>H001156 4/30/2022 68180-217-06 H001627 5/31/2022 68180-217-06 H001947 6/30/2022 68180-217-06 H002242 8/31/2022 68180-217-06 H101826 7/31/2023 68180-217-06 H001155 4/30/2022 68180-217-09 H001355 5/31/2022 68180-217-09 H001356 5/31/2022 68180-217-09 H001357 5/31/2022 68180-217-09 H001358 5/31/2022 68180-217-09 H001359 5/31/2022 68180-217-09 H001371 5/31/2022 68180-217-09 H001372 5/31/2022 68180-217-09 H001373 5/31/2022 68180-217-09 H001374 5/31/2022 68180-217-09 H001375 5/31/2022 68180-217-09 H001628 5/31/2022 68180-217-09 H001629 5/31/2022 68180-217-09 H001630 6/30/2022 68180-217-09 H001645 6/30/2022 68180-217-09 H001646 6/30/2022 68180-217-09 H001647 6/30/2022 68180-217-09 H001798 6/30/2022 68180-217-09 H001799 6/30/2022 68180-217-09 H001882 6/30/2022 68180-217-09 H001883 6/30/2022 68180-217-09 H001948 6/30/2022 68180-217-09 H001949 6/30/2022 68180-217-09 H001985 6/30/2022 68180-217-</p>	<p>Class II</p>	<p>Lupin Pharmaceuticals Inc.</p>



A Public Entity

Inland Empire Health Plan

		09 H001986 6/30/2022 68180-217-09 H001987 7/31/2022 68180-217-09 H001988 7/31/2022 68180-217-09 H001989 7/31/2022 68180-217-09 H001990 7/31/2022 68180-217- 09 H002243 8/31/2022 68180-217-09 H002244 8/31/2022 68180-217-09 H002245 8/31/2022 68180-217-09 H002315 8/31/2022 68180-217-09 H002316 8/31/2022 68180-217- 09 H002317 8/31/2022 68180-217-09 H002318 8/31/2022 68180-217-09 H002319 8/31/2022 68180-217-09 H002320 8/31/2022 68180-217-09 H002321 8/31/2022 68180-217- 09 H002322 8/31/2022 68180-217-09 H002323 8/31/2022 68180-217-09 H002324 8/31/2022 68180-217-09 H002632 9/30/2022 68180-217-09 H002633 9/30/2022 68180-217- 09 H002634 9/30/2022 68180-217-09 H002635 9/30/2022 68180-217-09 H002636 9/30/2022 68180-217-09 H002765 9/30/2022 68180-217-09 H002766 9/30/2022 68180-217- 09 H002767 9/30/2022 68180-217-09 H002768 9/30/2022 68180-217-09 H002769 9/30/2022 68180-217-09 H002770 9/30/2022 68180-217-09 H003194 11/30/2022 68180- 217-09 H003195 11/30/2022 68180-217-09 H100009 12/31/2022 68180-217-09 H100010 12/31/2022 68180-217-09 H100021 12/31/2022 68180-217-09 H100022 12/31/2022 68180-217-09 H100023 12/31/2022 68180-217-09 H100029 12/31/2022 68180-217-09 H100030 12/31/2022 68180-217-09 H100342 1/31/2023 68180-217-09 H100343 1/31/2023 68180-217-09 H100344 1/31/2023 68180-217- 09 H100345 1/31/2023 68180-217-09 H100346 1/31/2023 68180-217-09 H100374 1/31/2023 68180-217-09 H100375 1/31/2023 68180-217-09 H100376 1/31/2023 68180-217- 09 H100377 1/31/2023 68180-217-09 H100378 1/31/2023 68180-217-09 H100452 1/31/2023 68180-217-09 H100453 1/31/2023 68180-217-09 H100454 2/28/2023 68180-217- 09 H100458 2/28/2023 68180-217-09 H100459 2/28/2023 68180-217-09 H100652 2/28/2023 68180-217-09 H100653 2/28/2023 68180-217-09 H100654 2/28/2023 68180-217- 09 H100655 2/28/2023 68180-217-09 H100656 2/28/2023 68180-217-09 H100687 2/28/2023 68180-217-09 H100688 2/28/2023 68180-217-09 H100689 2/28/2023 68180-217- 09 H100703 2/28/2023 68180-217-09 H100704 2/28/2023 68180-217-09 H100891 3/31/2023 68180-217-09 H100892 3/31/2023 68180-217-09 H100902 3/31/2023 68180-217- 09 H100903 3/31/2023 68180-217-09 H100904 3/31/2023 68180-217-09 H100905 3/31/2023 68180-217-09 H100936 3/31/2023 68180-217-09 H100937 3/31/2023 68180-217- 09 H100938 3/31/2023 68180-217-09 H101153 5/31/2023 68180-217-09 H101154 5/31/2023 68180-217-09 H101155 5/31/2023 68180-217-09 H101156 5/31/2023 68180-217- 09 H101157 5/31/2023 68180-217-09 H101158 5/31/2023 68180-217-09 H101159 5/31/2023 68180-217-09 H101294 5/31/2023 68180-217-09 H101295 5/31/2023 68180-217- 09 H101296 5/31/2023 68180-217-09 H101297 5/31/2023 68180-217-09 H101325 5/31/2023 68180-217-09 H101326 6/30/2023 68180-217-09 H101327 6/30/2023 68180-217- 09 H101328 6/30/2023 68180-217-09 H101349 6/30/2023 68180-217-09 H101350 6/30/2023 68180-217-09 H101351 6/30/2023 68180-217-09 H101352 6/30/2023 68180-217- 09 H101482 6/30/2023 68180-217-09 H101483 6/30/2023 68180-217-09 H101606 7/31/2023 68180-217-09 H101618 7/31/2023 68180-217-09 H101619 7/31/2023 68180-217- 09 H101620 7/31/2023 68180-217-09 H101621 7/31/2023 68180-217-09 H101827 7/31/2023 68180-217-09 H101828 7/31/2023 68180-217-09 H101829 7/31/2023 68180-217- 09 H101857 7/31/2023 68180-217-09	
--	--	--	--

10801 6th St., Suite 120, Rancho Cucamonga, CA 91730
Tel (909) 890-2049 Fax (909) 890-2058
Visit our web site at: www.iehp.org

A Public Entity



A Public Entity

Inland Empire Health Plan

		<p>H101858 7/31/2023 68180-217-09 H101911 7/31/2023 68180-217-09 H101912 7/31/2023 68180-217-09 H101913 7/31/2023 68180-217-09 H102455 10/31/2023 68180-217-09 H102456 10/31/2023 68180-217-09 H102457 10/31/2023 68180-217-09 H102458 10/31/2023 68180-217-09 H102485 10/31/2023 68180-217-09 H102489 10/31/2023 68180-217-09 H102490 10/31/2023 68180-217-09 H102491 10/31/2023 68180-217-09</p>		
<p>Losartan Potassium and Hydrochlorothiazide 100 mg/12.5 mg Tablets</p>	<p>NDC: 68180-0216-06; 68180-0216-09</p>	<p>H001878 6/30/2022 68180-216-06 H002178 7/31/2022 68180-216-06 H002626 9/30/2022 68180-216-06 H102149 9/30/2023 68180-216-06 H001600 5/31/2022 68180-216-09 H001601 5/1/2022 68180-216-09 H001625 5/31/2022 68180-216-09 H001626 5/31/2022 68180-216-09 H001794 6/30/2022 68180-216-09 H001795 6/30/2022 68180-216-09 H001796 6/30/2022 68180-216-09 H001797 6/30/2022 68180-216-09 H001879 6/30/2022 68180-216-09 H001880 6/30/2022 68180-216-09 H001881 6/30/2022 68180-216-09 H001942 6/30/2022 68180-216-09 H001943 6/30/2022 68180-216-09 H001944 6/30/2022 68180-216-09 H001945 6/30/2022 68180-216-09 H001946 6/30/2022 68180-216-09 H002179 7/31/2022 68180-216-09 H002180 7/31/2022 68180-216-09 H002181 8/31/2022 68180-216-09 H002182 8/31/2022 68180-216-09 H002183 8/31/2022 68180-216-09 H002237 8/31/2022 68180-216-09 H002238 8/31/2022 68180-216-09 H002239 8/31/2022 68180-216-09 H002240 8/31/2022 68180-216-09 H002241 8/31/2022 68180-216-09 H002627 9/30/2022 68180-216-09 H002628 9/30/2022 68180-216-09 H002629 9/30/2022 68180-216-09 H002630 9/30/2022 68180-216-09 H002631 9/30/2022 68180-216-</p>	<p>Class II</p>	<p>Lupin Pharmaceuticals Inc.</p>



A Public Entity

Inland Empire Health Plan

		<p>09 H002979 11/30/2022 68180-216-09 H002980 11/30/2022 68180-216-09 H002981 11/30/2022 68180-216-09 H002982 11/30/2022 68180-216-09 H002983 11/30/2022 68180-216-09 H100112 12/31/2022 68180-216-09 H100113 12/31/2022 68180-216-09 H100114 12/31/2022 68180-216-09 H100115 12/31/2022 68180-216-09 H100116 12/31/2022 68180-216-09 H100156 12/31/2022 68180-216-09 H100157 12/31/2022 68180-216-09 H100622 2/28/2023 68180-216-09 H100623 2/28/2023 68180-216-09 H100624 2/28/2023 68180-216- 09 H100625 2/28/2023 68180-216-09 H100626 2/28/2023 68180-216-09 H100627 2/28/2023 68180-216-09 H100628 2/28/2023 68180-216-09 H100629 2/28/2023 68180-216- 09 H100939 4/30/2023 68180-216-09 H100940 4/30/2023 68180-216-09 H100941 4/30/2023 68180-216-09 H100942 4/30/2023 68180-216-09 H100943 4/30/2023 68180-216- 09 H101094 5/31/2023 68180-216-09 H101095 5/31/2023 68180-216-09 H101096 5/31/2023 68180-216-09 H101097 5/31/2023 68180-216-09 H101098 5/31/2023 68180-216- 09 H101151 5/31/2023 68180-216-09 H101152 5/31/2023 68180-216-09 H101290 5/31/2023 68180-216-09 H101291 5/31/2023 68180-216-09 H101292 5/31/2023 68180-216- 09 H101293 5/31/2023 68180-216-09 H101323 5/31/2023 68180-216-09 H101324 5/31/2023 68180-216-09 H101823 7/31/2023 68180-216-09 H101824 7/31/2023 68180-216- 09 H101825 7/31/2023 68180-216-09 H101853 8/31/2023 68180-216-09 H101854 8/31/2023 68180-216-09 H101855 8/31/2023 68180-216-09 H101856 8/31/2023 68180-216- 09 H102127 9/30/2023 68180-216-09 H102128 9/30/2023 68180-216-09 H102129 9/30/2023 68180-216-09 H102130 9/30/2023 68180-216-09 H102150 9/30/2023 68180-216- 09 H102151 9/30/2023 68180-216-09 H102152 9/30/2023 68180-216-09 H102153 9/30/2023 68180-216-09 H102154 9/30/2023 68180-216-09 H102155 9/30/2023 68180-216- 09 H102201 9/30/2023 68180-216-09 H102223 9/30/2023 68180-216-09 H102268 9/30/2023 68180-216-09 H102269 9/30/2023 68180-216-09 H102270 9/30/2023 68180-216- 09 H102271 9/30/2023 68180-216-09</p>		
Halobetasol Propionate Ointment 0.05% Net Wt., 50 gram tube	NDC: 63739-0998-67	15720 Exp. 06/30/2022; 16449 Exp. 02/28/2023; 16450 Exp. 02/26/2023	Class II	McKesson Corporation dba McKesson Drug Company
Lidocaine Hydrochloride Topical Solution USP 4% (40 mg/mL), 50 mL bottle	NDC: 63739-0977-64	15597, Exp.: 05/31/2023; 16305, Exp.: 12/23/2023; 16334, 16340, 16346, 16356, 16357 Exp. 01/31/2024	Class II	McKesson Corporation dba McKesson Drug Company
Lidocaine Prilocaine Cream USP, 2.5%/2.5% Net Wt. 30 gram tube	NDC: 63739-0054-66	16876 Exp. 05/31/2023	Class II	McKesson Corporation dba McKesson Drug Company
Betamethasone Dipropionate Ointment USP, 0.05%* (Augmented) (Potency expressed as	NDC: 63739-0996-65	15644 Exp. 05/31/2022	Class II	McKesson Corporation dba McKesson Drug Company



A Public Entity

Inland Empire Health Plan

betamethasone), 15 gram tube				
Erythromycin Topical Gel USP, 2%, Net Wt 60 g tube	NDC: 63739-0053-68	15723 Exp. 06/30/2022	Class II	McKesson Corporation dba McKesson Drug Company
Pantoprazole Sodium 20 mg Delayed-Release Tablets	NDC: 13668-0096-90	BA34G021, BA34G022 Exp. 09/2022	Class II	Torrent Pharma Inc
Lansoprazole Delayed-Release 30 mg Orally Disintegrating Tablets	NDC: 43598-0561-78	T2000645 Exp. 07/2022	Class II	Dr. Reddy's Laboratories, Inc.
Losartan Potassium 25mg Tablets	NDC: 33342-0044-10; 33342-0044-44	BLH2002A, BLH2003B, BLH2004A Exp. 11/2022	Class II	Macleods Pharma Usa Inc
Losartan Potassium 50 mg Tablets	NDC: 33342-0045-07; 33342-0045-10; 33342-0045-44	BLI2002A, BLI2004A Exp. 11/2022; BLI2104B Exp. 05/2023	Class II	Macleods Pharma Usa Inc
Losartan Potassium 100 mg Tablets	NDC: 33342-0046-07; 33342-0046-10; 33342-0046-44	BLI2107B Exp. 06/2023; BLI2101A, BLI2103A Exp. 12/2022; BLI2105A Exp. 05/2023	Class II	Macleods Pharma Usa Inc
Losartan Potassium - Hydrochlorothiazide 50 mg/12.5 mg Tablets	NDC: 33342-0050-07; 33342-0050-10; 33342-0050-44	BLK2107B, BLK2104A Exp. 05/2023; BLK2101A Exp. 01/2025; BLK2102A Exp. 02/2025; BLK2103B, BLK2103C Exp. 02/2023	Class II	Macleods Pharma Usa Inc
Losartan Potassium - Hydrochlorothiazide 100 mg/25 mg Tablets	NDC: 33342-0052-07; 33342-0052-10; 33342-0052-44	BLM2106B, BLM2106A, BLM2104A Exp. 05/2023; BLM2101A Exp. 01/2025; BLM2102A, BLM2103B Exp. 02/2023; BLM2110A Exp. 06/2023	Class II	Macleods Pharma Usa Inc
Losartan Potassium - Hydrochlorothiazide 100 mg/12.5 mg Tablets	NDC: 33342-0051-07; 33342-0051-10; 33342-0051-44	BLL2107B, BLL2104A Exp. 05/2023 ; BLL2101A Exp. 01/2025; BLL2102A Exp. 02/2025; BLL2103B Exp. 02/2023	Class II	Macleods Pharma Usa Inc
Alprazolam XR 3 mg Extended-Release Tablets	NDC: 59762-0068-01	EH8348 Exp. 08/2023	Class II	Viartis Inc



A Public Entity

Inland Empire Health Plan

Norepinephrine 8mg in 0.9% Sodium Chloride 250 mL bag	NDC: 70004-0078-40	1222035815 Exp. 07/10/2022	Class II	SCA Pharmaceuticals
Fentanyl 2mcg/ml and Bupivacaine 0.125% in 0.9% Sodium Chloride 100 mL bags	NDC: 70004-0231-32	1222035837 Exp. 07/22/2022; 1222035804 Exp. 07/25/2022	Class II	SCA Pharmaceuticals
Vancomycin HCl 1.5 g in 0.9% Sodium Chloride, 500 mL bags	NDC: 70004-0924-44	1222035839 Exp. 08/09/2022	Class II	SCA Pharmaceuticals
SyrSpend SF Suspending Base, Cherry Flavored	NDC: 51552-1123-05; 51552-1123-09	A67185, A67186 Exp. 08/31/2024	Class I	Fagron, Inc
Esomeprazole Magnesium 20 mg Delayed-Release Capsules, packaged in Unit Dose Blister Cards of 6 (10 cards of 6 Capsules each per carton)	NDC: 42292-0009-16	3112743 Exp. 04/30/2023; 3112582 Exp. 03/31/2023; 3110438, 3111708, 3111120 Exp. 07/31/2022	Class II	Mylan Institutional, Inc. (d.b.a. UDL Laboratories)
Esomeprazole Magnesium 40 mg Delayed-Release Capsules, packaged in Unit Dose Blister Cards of 6 (10 cards of 6 Capsules each per carton)	NDC: 42292-0010-16	3110437, 3111409, 3110785 Exp. 07/31/2022; 3112173 Exp. 11/30/2022	Class II	Mylan Institutional, Inc. (d.b.a. UDL Laboratories)
Xanax XR (alprazolam) 3 mg extended-release Tablets	NDC: 0009-0068-07	DX7983 Exp. 02/28/2023	Class II	Viatrix Inc
MVASI (bevacizumab-awwb), Injection, For Intravenous Infusion After Dilution, 100 mg/4 ml, Single dose vial	NDC: 55513-0206-01	1142258, 1143196 Exp. 09/2024	Class II	Amgen, Inc.
Anagrelide 0.5 mg Capsules	NDC: 00172-5241-60	GD01090 Exp. 05/2022	MW	Teva Pharmaceuticals USA
Milk of Magnesia (Magnesium Hydroxide) 2400 mg/30 mL, 30 mL cup, packaged in 10 cups per tray, 10 trays per carton	NDC: 00904-6846-73	20024A, 20025A Exp. 03/2022	Class I	Plastikon Healthcare LLC
Magnesium Hydroxide 1200mg, Aluminum Hydroxide 1200mg, Simethicone 120mg, 30 mL cup, packaged in 10 cups per tray, 10 trays per carton	NDC: 00904-6838-73	21067A Exp. 06/2023	Class I	Plastikon Healthcare LLC



A Public Entity

Inland Empire Health Plan

Humalog KwikPen, Insulin lispro injection, U-100, 100 units per mL, 5x3 mL Prefilled Pens per box	NDC: 00002-8799-59; 00002-7516-59	Not Provided	Class I	Cardinal Health Inc.
Acetaminophen Oral Solution, 650mg/ 20.3 mL cup, packaged in 10 cups per tray, 10 trays per carton	NDC: 00904-6820-76	20040A Exp. 05/2022	Class II	Plastikon Healthcare LLC
Milk of Magnesia (Magnesium Hydroxide), 2400 mg/30 mL, 30 mL cup, packaged in 10 cups per tray, 10 trays per carton	NDC: 00904-6846-73	20041A Exp. 05/2022	Class II	Plastikon Healthcare LLC
Magnesium Hydroxide 1200mg, Aluminum Hydroxide 1200mg, Simethicone 120mg, 30 mL cup, packaged in 10 cups per tray, 10 trays per carton	NDC: 00904-6838-73	20042A, 20043A, 20045A, 20046A, 20047A Exp. 05/2022	Class II	Plastikon Healthcare LLC
Trulicity (dulaglutide) injection, 1.5 mg/0.5mL once weekly, 4 Single-Dose Pens	NDC: 00002-1434-80	D482749A Exp. 10/15/2023	Class II	Cardinal Health Inc.
Trulicity (dulaglutide) injection, 0.75 mg/0.5mL once weekly, 4 Single-Dose Pen	NDC: 00002-1433-80	D484557A Exp. 10/25/2023	Class II	Cardinal Health Inc.
Accupril (Quinapril HCl) 10 mg Tablets	NDC: 00071-0530-23	DR9639 Exp. 05/31/2023	Class II	Pfizer Inc.
Accupril (Quinapril HCl) 20 mg Tablets	NDC: 00071-0532-23	DX8682, DG1188 Exp. 05/31/2022	Class II	Pfizer Inc.
Accupril (Quinapril HCl) 40 mg Tablets	NDC: 00071-0535-23	DX6031 Exp. 05/31/2023; CK6260 Exp. 05/31/2022;	Class II	Pfizer Inc.
GaviLyte -C (Polyethylene Glycol 3350, 240 g) and electrolytes for Oral Solution with flavor pack	NDC: 43386-0060-19	S001132 Exp. 07/2022	Class II	Lupin Pharmaceuticals Inc.

I = Class I Recall, II = Class II Recall, MW = Market Withdrawal

Additional information can be found at:

1. FDA Recalls, Market Withdrawals, & Safety Alerts:
<https://www.fda.gov/Safety/Recalls/default.htm>
2. FDA Enforcement Report:

10801 6th St., Suite 120, Rancho Cucamonga, CA 91730
Tel (909) 890-2049 Fax (909) 890-2058
Visit our web site at: www.iehp.org

A Public Entity



A Public Entity

Inland Empire Health Plan

<http://www.fda.gov/Safety/Recalls/EnforcementReports/default.htm>

3. IEHP Safety Resources:

<https://ww3.iehp.org/en/providers/pharmaceutical-services/clinical-information/safety-resources/>

If you have any questions or comments regarding this recall, please call IEHP Pharmaceutical Services Department at 909-890-2049, 8am – 5pm (PST), Monday through Friday.

Sincerely,

IEHP Pharmaceutical Services